Market Overview

UPDATE: BMO Capital Markets Raises PT on Isis Pharmaceuticals Following Development Head Meeting

Related ISIS
Isis Pharmaceuticals Earns $4M from Achaogen For The Initiation Of A Phase 3 Study Of Plazomicin
How Raytheon Company And General Dynamics Corporation Could Benefit From The ISIL Announcement
Making Money With Charles Payne: 08/29/14 (Fox Business)

In a report published Friday, BMO Capital Markets analyst Jim Birchenough reiterated an Outperform rating on Isis Pharmaceuticals (NASDAQ: ISIS), and raised the price target from $22.00 to $31.00.

In the report, Birchenough noted, “The BMO Capital Markets US biotechnology team hosted a meeting this week with Isis Pharmaceuticals SVP of Clinical Development Dr. Richard Geary. Focus of the meeting was on a burgeoning pipeline of antisense oligonucleotide (ASO) therapeutics following recent approval of its first ASO therapeutic KYNAMRO. With 28 different ASO therapeutics in development, primary focus was on key late stage programs including wholly owned ISISApoC3-Rx for severe triglyceride elevation as well as partnered programs for ISIS-SMN-Rx for spinal muscular atrophy (SMA) and TTR associated familial amyloid polyneuropathy (FAP).”

Isis Pharmaceuticals closed on Thursday at $19.41.

Latest Ratings for ISIS

DateFirmActionFromTo
Aug 2014BMO CapitalMaintainsOutperform
Aug 2014Laidlow & Co.Initiates Coverage onBuy
May 2014JP MorganMaintainsNeutral

View More Analyst Ratings for ISIS
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Price Target Analyst Ratings

 

Related Articles (ISIS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters